SeaStar Medical Secures $23.9M Funding, Hits 50% Enrollment in AKI Trial
SeaStar Medical added 13 pediatric hospital customers, raising its QUELIMMUNE base to 16, secured $23.9 million in capital, and cut $3.1 million in liabilities. It enrolled 181 of 339 patients (over 50%) in its NEUTRALIZE-AKI trial and projects roughly $2 million in net product revenue for 2026.
1. Clinical Enrollment Milestones
SeaStar Medical’s pivotal NEUTRALIZE-AKI trial has enrolled 181 of 339 adult AKI patients, surpassing 50% of its target; the company also initiated a cardio-renal study in chronic heart failure patients awaiting LVAD implantation.
2. Pediatric Therapy Adoption
The company expanded its QUELIMMUNE pediatric AKI therapy to 16 top-ranked children’s hospitals by adding 13 new sites and completed enrollment of 50 patients in the FDA-mandated SAVE Registry, with 76% surviving 60 days and 71% surviving 90 days.
3. Financial Strength and 2026 Outlook
SeaStar strengthened its balance sheet with $23.9 million in new capital and a $3.1 million drop in liabilities, and it anticipates about $2 million in net product revenue for 2026 while preparing modular PMA submissions to expedite FDA review.